Constellation Pharmaceuticals (NASDAQ:CNST) issued its quarterly earnings data on Thursday. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14), Fidelity Earnings reports.
NASDAQ:CNST traded down $0.23 during trading hours on Friday, reaching $5.86. 6,229 shares of the stock were exchanged, compared to its average volume of 19,381. Constellation Pharmaceuticals has a 52 week low of $5.57 and a 52 week high of $12.21.
A number of equities research analysts have weighed in on CNST shares. Cann started coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They set an “outperform” rating and a $21.00 price objective for the company. Oppenheimer assumed coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They set an “outperform” rating and a $21.00 price objective for the company. Zacks Investment Research raised Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Monday, October 15th. JPMorgan Chase & Co. assumed coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They set an “overweight” rating and a $17.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They set an “outperform” rating and a $19.00 target price on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Constellation Pharmaceuticals has an average rating of “Buy” and a consensus target price of $17.15.
TRADEMARK VIOLATION WARNING: “Constellation Pharmaceuticals (CNST) Announces Earnings Results” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/10/constellation-pharmaceuticals-cnst-announces-earnings-results.html.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
See Also: How does a reverse stock split work?
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.